A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
Phase of Trial: Phase II/III
Latest Information Update: 19 Aug 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Connective tissue disorders; Dermatomyositis; Interstitial lung diseases; Polymyositis; Scleroderma
- Focus Therapeutic Use
- Acronyms RECITAL
- 25 Mar 2019 Status changed from completed to recruiting.
- 25 Mar 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 25 Mar 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.